Search

Search Constraints

You searched for: Author/Creator Serrano, E.

Search Results

21. MYC inhibition by OMO-103 induces immune cell recruitment in preclinical models of NSCLC and modulates the cytokine and chemokine profiles of Phase I patients showing stable disease. (October 2022)

22. MYC inhibition by Omomyc as a therapeutic strategy for (KRAS-mutated) colorectal cancer. (October 2022)

23. Omomyc as a novel therapeutic strategy against metastatic triplenegative breast cancer, alone and in combination with the standard of care. (October 2022)

24. Omomyc downregulates MYC transcriptional signature in preclinical models of solid tumours and shows long half-life in tumour tissue. (October 2022)

25. Omomyc mini-protein can be directly and continuously delivered to the brain to prevent glioblastoma in patient-derived xenograft mouse models. (October 2022)

27. Past, present and future of chamois science. Issue 4 (22nd April 2022)